Enzo Biochem, Inc. Stock Börse Stuttgart

Equities

EZB

US2941001024

Biotechnology & Medical Research

Real-time Estimate Tradegate 08:24:15 2024-07-11 am EDT 5-day change 1st Jan Change
0.993 EUR +1.85% Intraday chart for Enzo Biochem, Inc. +6.56% -20.73%
Sales 2022 107M 98.63M Sales 2023 31.06M 28.61M Capitalization 73.6M 67.8M
Net income 2022 -18M -16.58M Net income 2023 20M 18.42M EV / Sales 2022 1.07 x
Net cash position 2022 1.02M 936K Net cash position 2023 75.38M 69.43M EV / Sales 2023 -0.06 x
P/E ratio 2022
-6.24 x
P/E ratio 2023
3.59 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 75.92%
More Fundamentals * Assessed data
Dynamic Chart
1 week+6.56%
Current month+3.17%
1 month-8.88%
3 months-11.36%
6 months-22.00%
Current year-20.73%
More quotes
1 week
0.92
Extreme 0.92
0.98
1 month
0.92
Extreme 0.915
1.09
3 years
0.92
Extreme 0.915
3.54
5 years
0.92
Extreme 0.915
4.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 10-12-31
Founder 81 76-07-31
Director of Finance/CFO 47 -
Members of the board TitleAgeSince
Chairman 64 23-10-25
Director/Board Member 58 20-11-16
Director/Board Member 50 22-01-02
More insiders
Date Price Change
24-07-11 0.98 +0.51%
24-07-10 0.975 +3.17%
24-07-09 0.945 +0.53%
24-07-08 0.94 +2.17%
24-07-05 0.92 -0.54%

Delayed Quote Börse Stuttgart, July 11, 2024 at 04:40 am EDT

More quotes
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
More about the company